Actor Portrayal


INVEGA HAFYERA® is the only medication that treats schizophrenia with 1 dose every 6 months.

Since shifting to being treated with INVEGA HAFYERA®, my life is less defined by schizophrenia medication, and I now experience 6 months of symptom control with each dose.

– A schizophrenia community member

How to Start Treatment With INVEGA HAFYERA®

INVEGA HAFYERA® is different from both INVEGA SUSTENNA® and INVEGA TRINZA®, in that it's an injection given twice a year, every 6 months.

Your healthcare professional will start treatment for your schizophrenia with INVEGA SUSTENNA®, the once-monthly version of the active medication in INVEGA HAFYERA®. You need to be on INVEGA SUSTENNA® for at least 4 months with the last 2 doses being 156 mg or 234 mg. Then you can transition to INVEGA TRINZA® after being adequately treated for at least 4 months, or you can transition to INVEGA HAFYERA®.

If you and your healthcare professional decide that you should transition to INVEGA TRINZA® before starting on INVEGA HAFYERA®, you will need to be adequately treated with INVEGA TRINZA® for one 3-month cycle (one dose of 546 mg or 819 mg).

It's important to be patient, because starting any new medication can be challenging. Work with your healthcare professional to find the right dose of INVEGA HAFYERA® that will help control schizophrenia symptoms with the fewest side effects.It's very important that you go to all of your injection appointments. If you miss an injection, talk to your treatment team as soon as possible. If you are experiencing symptoms or side effects, be sure to let your healthcare professional know. You and your treatment team members can also discuss options to help remember your injection appointments, or if you might be able to receive your injection at a place near you other than your healthcare professional's office.

Clinical Trial Results


A long-term, global clinical study was conducted to show whether INVEGA HAFYERA® was as effective as (noninferiority) INVEGA TRINZA® in symptom control with similar safety and side effects.

In this study, 92.5% of patients treated with INVEGA HAFYERA® and 95% of patients treated with INVEGA TRINZA® did not experience an episode at 12 months.

  • Results were based on a 12-month, randomized, double-blind, noninferiority trial
  • The main purpose of this study was to determine if INVEGA HAFYERA® worked as well as INVEGA TRINZA® for delaying relapse in the double-blind phase
  • 1.3% of patients in the INVEGA HAFYERA® group and 0.4% of patients in the INVEGA TRINZA® group discontinued due to adverse reactions

The most common side effects of INVEGA HAFYERA® include:

  • Upper respiratory tract infections (12%)
  • Injection site reactions (11%)
  • Weight gain (9%)
  • Headache (7%)
  • Movement disorders including feeling restlessness or difficulty sitting still, slow movements, tremors, stiffness, and shuffling walk (7%)

INVEGA HAFYERA® is to be used after adequate treatment with either INVEGA SUSTENA® for at least 4 months or INVEGA TRINZA® following at least one 3-month injection cycle at an appropriate dose.

Patients who were relapse-free after 1 year in the noninferiority study were eligible to continue in this study.

96.1% of patients taking INVEGA HAFYERA® were relapse-free.

87% of patients completed 2 years of treatment with INVEGA HAFYERA® in a real-world, open-label extension study.

  • The most common (≥5%) adverse reactions were headache (13.5%), blood prolactin increased (10.7%), hyperprolactinemia (7.3%), diarrhea (6.2%), weight increased (5.1%), and nasopharyngitis (5.1%)
  • 7 out of 178 patients who entered the open-label phase relapsed.
  • 154 patients completed the 2-year, open-label study
  • The open-label phase of the study was conducted in 6 countries, excluding the United States

Watch the Change Exhibit

Learn about a path to a twice-yearly treatment with INVEGA HAFYERA®.


Getting Started With LAIs

to Top